Biological therapy, also known as immunotherapy, is a form of cancer treatment that uses the body's immune system to fight cancer. It involves the use of substances made from living organisms or their products to stimulate or enhance the immune system's ability to target and destroy cancer cells. Numerous companies are actively involved in the development and commercialization of cancer biological therapies.
Biocon acquires Viatris' biosimilar insulin portfolio: November 2023 deal strengthens Biocon's presence in the diabetes care market and expands access to affordable insulin options in the region.
AstraZeneca partners with Chinese biotech companies: AstraZeneca is actively forging partnerships with local players like Jiangsu Hengrui Medicine and Mabtech to develop and commercialize innovative cancer drugs for the Asian market.
Roche launches Tecentriq (atezolizumab) for first-line non-small cell lung cancer in Japan: December 2023 approval expands treatment options for lung cancer patients in Japan.
Eli Lilly receives China approval for Verzenio (abemaciclib) for metastatic breast cancer: October 2023 approval opens up access to a targeted therapy for Chinese patients with advanced breast cancer.
List of Asia Pacific Cancer Biological Therapy Key Companies in the Market
APAC Cancer Biological Therapy Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)